Bergenbio appoints former crct ceo foden to board as bgb324 lead
oncology candidate approaches clinic
Bergen, norway--(business wire)--bergenbio, an emerging oncology biopharma, today announced the appointment of dr sue foden to its board of directors. foden was one of the founders of cancer research uk and also served as ceo of both cancer research campaign technology ltd and cancer research ventures ltd. she was also an investment director at merlin biosciences, advisor on several eu projects and currently holds a range of directorships including source bioscience plc, elara gmbh and vectura plc. following a recent successful fundraising led by sarsia seed, foden’s appointment represents a further strengthening of the company as it gears up to taking its lead programme bgb324, a first in class axl inhibitor, into phase i trials in 2012. richard godfrey, bergenbio’s ceo, welcomed foden’s appointment: “sue brings to bergenbio both a wealth of experience in oncology pipeline development and a wide network of commercial contacts. we hope to utilize both as we bring bgb324, our proprietary axl inhibitor, to clinic next year and also broaden our portfolio of other novel oncology targets based around emt in particular. dr foden added: “the quality of the science and the strength of the team initially attracted me to bergenbio. i also see a real breadth of commercialisation opportunities and the possibility to build an attractive pipeline for investors over the next few years.” notes to editors bergenbio as is a biopharmaceutical company located in bergen, norway and founded on proprietary platform technology called cellselect™. the cellselect technology uses information from rnai screening studies to identify novel drug targets involved in disease. bergenbio has a deep understanding of cancer biology and in particular the tumor micro-environment, emt and mechanisms of drug resistance. having generated significant fee for service revenues with cellselect, bergenbio as is now transitioning to developing first in class oncology therapeutics through to phase ii. website: www.bergenbio.com
CRCT Ratings Summary
CRCT Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission